Cerenovus’ TruFill n-BCA Liquid Embolic System Evaluated for Treatment of Chronic Subdural Hematoma

June 9, 2021—Cerenovus, a Johnson & Johnson Medical Devices Companies, announced that the first patient has been enrolled in the company-sponsored MEMBRANE study evaluating the safety and efficacy of its investigational TruFill n-Butyl cyanoacrylate liquid embolic system in the embolization of the middle meningeal artery (MMA) for treatment of chronic subdural hematoma (cSDH) as adjunct to surgical evacuation or as a stand-alone treatment.

According to the Johnson & Johnson announcement, the randomized MEMBRANE study will enroll > 300 patients at 35 sites across the United States during the next 2 years. Patients will be followed for 1 year.

The study’s primary investigators are Ansaar Rai, MD, and Christopher Kellner, MD. Dr. Rai, who enrolled the first patient in the study, is Professor and Chair of Neuroradiology at Rockefeller Neuroscience Institute, West Virginia University School of Medicine in Morgantown, West Virginia. Dr. Kellner is Assistant Professor in Neurosurgery and Director of the Intracerebral Hemorrhage Program at Mount Sinai Health System in New York, New York.

In the company’s announcement, Dr. Kellner commented, “The first patient enrollment in the MEMBRANE trial is an exciting milestone for our teams in evaluating MMA embolization as a treatment option for cSDH.”

Dr. Rai added, “We are looking forward to exploring the potential of providing physicians additional ways to address and manage this disease, especially in older adults who may be more at risk to undergo surgery.”